Sands Capital Ventures LLC Cuts Position in Candel Therapeutics, Inc. (NASDAQ:CADL)

Sands Capital Ventures LLC reduced its holdings in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) by 50.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 405,837 shares of the company’s stock after selling 405,900 shares during the quarter. Candel Therapeutics makes up approximately 0.8% of Sands Capital Ventures LLC’s holdings, making the stock its 10th biggest position. Sands Capital Ventures LLC owned approximately 1.36% of Candel Therapeutics worth $2,516,000 at the end of the most recent quarter.

Separately, Bank of New York Mellon Corp acquired a new position in shares of Candel Therapeutics during the 2nd quarter worth approximately $338,000. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Candel Therapeutics Trading Down 1.8 %

NASDAQ CADL opened at $7.54 on Friday. The company has a market cap of $224.36 million, a PE ratio of -5.89 and a beta of -0.94. Candel Therapeutics, Inc. has a 12 month low of $0.66 and a 12 month high of $14.30. The stock has a 50 day moving average of $6.13 and a 200-day moving average of $6.11. The company has a current ratio of 1.62, a quick ratio of 1.62 and a debt-to-equity ratio of 1.66.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.74) earnings per share for the quarter. On average, equities research analysts anticipate that Candel Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Charles Schoch sold 8,897 shares of the firm’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $5.97, for a total transaction of $53,115.09. Following the transaction, the insider now directly owns 72,404 shares of the company’s stock, valued at $432,251.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Paul Peter Tak sold 20,293 shares of Candel Therapeutics stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $5.97, for a total value of $121,149.21. Following the transaction, the chief executive officer now owns 353,263 shares in the company, valued at approximately $2,108,980.11. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Charles Schoch sold 8,897 shares of the business’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $5.97, for a total value of $53,115.09. Following the transaction, the insider now directly owns 72,404 shares of the company’s stock, valued at approximately $432,251.88. The disclosure for this sale can be found here. Insiders sold 89,783 shares of company stock worth $559,636 in the last quarter. 41.60% of the stock is currently owned by corporate insiders.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.